

## **Avacta Appoints Brian Hahn as Chief Financial Officer**

- ***Brian brings 25 years' senior financial and operational experience, including leading GlycoMimetics' Nasdaq IPO and financial operations***

**LONDON and PHILADELPHIA - Jan 13, 2025 - Avacta Therapeutics (AIM: AVCT)**, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer (CFO).

Mr Hahn brings more than 25 years of senior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company's 2014 initial public offering (IPO) on Nasdaq and the build-out of its finance, accounting, investor relations and corporate affairs functions.

He has worked with life science companies from early stages through product launch, has significant experience in dealing with US healthcare investors, having been involved in multiple IPOs and has raised over 700 million in capital. He has broad experience in developing strategic plans, business development deals, building strong organizations and establishing strong accounting and control systems which ensure Sarbanes-Oxley compliance.

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions' Advisory Committee on Small and Emerging Companies. Prior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of increasing financial leadership responsibility, including Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.

He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

"Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage," said **Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta**. "His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange."

"What drew me to Avacta was not just the company's innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families," commented **Brian Hahn**. "The company has built a strong foundation with its pre|CISION® and Affimer® platforms, and I look forward to leveraging my experience to help accelerate Avacta's growth and strengthen its position in both the U.K. and U.S. capital markets."

**-Ends-**

**For further information from Avacta, please contact:**

**Avacta Group plc**[www.avacta.com](http://www.avacta.com)

Michael Vinegrad, Group Communications

Director

**Peel Hunt (Nomad and Broker)**James Steel / Chris Golden / Patrick  
Birkholm[www.peelhunt.com](http://www.peelhunt.com)**ICR Healthcare**Mary-Jane Elliott / Jessica Hodgson / Max  
Bennett[avacta@consilium-comms.com](mailto:avacta@consilium-comms.com)**Investor Contact**

Renee Leck

[renee@thrustsc.com](mailto:renee@thrustsc.com)

THRUST Strategic Communications

**Media Contact**

Carly Scaduto

[Carly@carlyscadutoconsulting.com](mailto:Carly@carlyscadutoconsulting.com)

Carly Scaduto Consulting

**About Avacta - [www.avacta.com](http://www.avacta.com)**

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION<sup>®</sup> platform. pre|CISION<sup>®</sup> is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION<sup>®</sup> peptide drug conjugates (PDC) or Affimer<sup>®</sup> drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGZGMMZZKGKZZ

